HSTO - Histogen perks up 7% on advancement of candidate for male pattern baldness

Dosing has been completed in a Phase 1b/2a clinical trial evaluating Histogen's (HSTO) lead candidate HST-001 for the treatment of androgenic alopecia (male pattern baldness).36 subjects, randomized 2:1 to receive HST-001 or placebo, received a total of 20 injections, 10 in the vertex scalp regin and five in each temporal region.Topline results should be available this quarter.HST-001, Hair Stimulating Complex, contains growth factors that play key roles in stimulating hair follicles and hair formation.Shares up 7% premarket on light volume.

For further details see:

Histogen perks up 7% on advancement of candidate for male pattern baldness